The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer

被引：0

作者：

Ching-Wen Huang

Hsiang-Lin Tsai

Yi-Ting Chen

Chun-Ming Huang

Cheng-Jen Ma

Chien-Yu Lu

Chao-Hung Kuo

Deng-Chyang Wu

Chee-Yin Chai

Jaw-Yuan Wang

机构：

[1] Kaohsiung Medical University,Graduate Institute of Medicine, College of Medicine

[2] Kaohsiung Medical University,Department of Surgery, Kaohsiung Municipal Hsiao

[3] Kaohsiung Medical University Hospital,Kang Hospital

[4] Kaohsiung Medical University,Division of Gastrointestinal and General Surgery, Department of Surgery

[5] Kaohsiung Medical University,Cancer Center, Kaohsiung Medical University Hospital

[6] Kaohsiung Medical University Hospital,Division of General Surgery Medicine, Department of Surgery

[7] Fooyin University,Program of Bachelor of Health Beauty, School of Medical and Health Sciences

[8] Kaohsiung Medical University,Department of Pathology, Kaohsiung Medical University Hospital

[9] Kaohsiung Medical University Hospital,Department of Radiation Oncology

[10] Kaohsiung Medical University,Graduate Institute of Clinical Medicine, College of Medicine

[11] Kaohsiung Medical University Hospital,Division of Gastroenterology, Department of Internal Medicine

[12] Kaohsiung Medical University,Department of Internal Medicine, Faculty of Medicine, College of Medicine

[13] Kaohsiung Medical University,Department of Pathology, Faculty of Medicine, College of Medicine

[14] Kaohsiung Medical University,Department of Surgery, Faculty of Medicine, College of Medicine

[15] Kaohsiung Medical University,undefined

来源：

BMC Cancer | / 13卷

关键词：

Epidermal growth factor receptor; Prognostic value; Metachronous; Synchronous; Metastatic colorectal cancer;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 356 条

[1]

Jemal A(2013)Cancer statistics, 2013 CA Cancer J Clin 63 11-30

[2]

Siegel R(2004)Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer BMC Cancer 4 38-456

[3]

Xu J(2006)Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma Ann Oncol 17 450-1174

[4]

Ward E(2008)EGFR antagonists in cancer treatment N Engl J Med 358 1160-2037

[5]

Teufel A(2011)Increased epidermal growth factor receptor expression at the invasive margin is a negative prognostic factor in colorectal cancer Int J Cancer 128 2031-835

[6]

Steinmann S(2006)Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery Ann Surg Oncol 13 823-108

[7]

Siebler J(2005)Impact of EGFR expression on colorectal cancer patient prognosis and survival Ann Oncol 16 102-108

[8]

Zanke C(2005)The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis Radiother Oncol 74 101-62

[9]

Hohl H(2005)Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer BMC Cancer 20 5-345

[10]

Adami B(2004)Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337-1810

← 1 2 3 4 5 6 7 8 9 10 →